Value Microcaps Free-For-All

[roguedolphin]

PTN....this one looks good technically and fundamentally as a good "10-bagger" possibility.

Palatin Technologies to Present at the UBS Global Life Sciences Conference
Monday September 26, 4:18 pm ET


CRANBURY, N.J., Sept. 26 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN - News) today announced that it will present at the UBS Global Life Sciences Conference at 9:30 a.m. Eastern Time on Tuesday, September 27, 2005 at the Grand Hyatt New York in New York City.
ADVERTISEMENT


Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies will provide an update on the Company's commercial and development programs. A live audio webcast of this presentation will be available at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company developing melanocortin-based therapeutics. The Company has one product (NeutroSpec(TM)) on the market generating revenue and a pipeline of product opportunities in development. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, the Company has formed partnerships with Mallinckrodt, a subsidiary of Tyco Healthcare, and King Pharmaceuticals. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Any statements contained in this press release that refers to future events or other non-historical matters are forward-looking statements. Palatin disclaims any intent or obligation to update any forward-looking statements. Such statements are based on Palatin's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: the inherent uncertainty associated with financial projections; and such risks and uncertainties as detailed from time to time in Palatin's public filings with the U.S. Securities and Exchange Commission, including but not limited to, Palatin's Annual Report on Form 10-K for the year ended June 30, 2005 and its Quarterly Reports on Form 10-Q for the quarterly periods ended September 30, 2004, December 31, 2004 and March 31, 2005.




--------------------------------------------------------------------------------
Source: Palatin Technologies, Inc.


Rogue